Glenmark Pharmaceuticals Limited (GLENMARK) advances its multi-country Phase 3 clinical trial for Trastuzumab rezetecan in platinum-resistant ovarian cancer.
Glenmark Pharmaceuticals Limited launches Methylene Blue Injection USP in USA, expanding access to affordable healthcare solutions.
Glenmark Pharmaceuticals Limited (GLENMARK) launches Winlevi® cream in key European markets, marking first NCE launch and strengthening dermatology portfolio.
Glenmark Pharmaceuticals Limited announces new development candidate ISB 2301, a first-in-class multispecific immune cells activator targeting solid tumors.
Glenmark Pharmaceuticals Limited (GLENMARK) launches Vancomycin Hydrochloride for Injection in USA, expanding access to quality, affordable medicines.
